2024 Volume 5, Issue 1: 1-27

DOI: https://doi.org/10.48185/jaai.v5i1.974

Integrative Approaches for Advancing Organoid Engineering: From Mechanobiology to Personalized Therapeutics

Zarif Bin Akhtar^{1,*}, Anik Das Gupta²

¹MPhil Research Postgraduate Student, Master of Philosophy (MPhil) in Machine Learning and Machine Intelligence, Department of Engineering, University of Cambridge, United Kingdom

²Master of Engineering in Electrical and Computer Engineering, Gina Cody school of Engineering and Computer Science, Concordia University, Montreal, Canada

Received: 16.01.2024 • Accepted: 07.03.2024 • Published: 20.03.2024 • Final Version: 27.04.2024

Abstract: This research manuscript aims to explore the integration of cutting-edge technologies in the field of organoid engineering for applications in personalized precision medicine. The research investigative exploration will delve into the multifaceted aspects of organoid research, incorporating mechanobiological modulation, ultrasound stimulation, and acoustofluidics to enhance the engineering of organoids. The focus will extend to the development of organoids-on-a-chip platforms with integrated biosensors, providing real-time monitoring capabilities for improved disease modeling and drug testing. Additionally, the manuscript will address the challenges and opportunities associated with large-scale manufacturing of organoids, emphasizing the scalability of regenerative medicine approaches. The proposed research will contribute to the advancement of 3D tissue models, micro physiological systems, and multi-organoid systems, offering a very comprehensive perspective on the potential of these systematic technologies in reshaping the landscape of personalized medicine.

Keywords: Artificial Intelligence (AI), Biomedical Engineering (BME), Biomolecular Engineering, Deep Learning, Machine Learning, Mechanobiological Modulation, Organoid Engineering.

1. Introduction

In the realm of regenerative medicine and biomolecular engineering, the advent of organoids has ushered in a new era of possibilities for personalized precision medicine. These three-dimensional (3D) miniature organs, cultivated in vitro, stand as remarkable replicas of their in vivo counterparts, holding the promise to revolutionize disease modeling, drug testing, and therapeutic development. The convergence of expertise from life sciences, physical sciences, engineering, and medical sciences has propelled organoid research into a highly interdisciplinary field, offering unprecedented opportunities to reshape biomedical research and healthcare practices.

This investigative exploration invites researchers to delve into the forefront of organoid engineering, exploring innovative approaches that span from mechanobiological modulation to the integration of cutting-edge technologies like ultrasound stimulation and acoustofluidics. The multifaceted nature of organoid research demands a comprehensive investigation into the intricacies

^{*} Corresponding Author: zarifbinakhtar@gmail.com; zarifbinakhtar@ieee.org;

of tissue engineering, the development of organoids-on-a-chip, and the engineering of brain assembloids.

As we navigate the complex landscape of personalized precision medicine, the potential applications of these technologies become increasingly apparent, paving the way for transformative advancements in the creation of functional in vitro models of organs and tissues.

This research manuscript endeavors to contribute significantly to this burgeoning field by synthesizing knowledge across diverse domains. We embark on a journey that extends from the mechanobiological modulation of organoids to the selective activation of piezo-channels through ultrasound stimulation.

The integration of biosensors within organoids-on-a-chip platforms, coupled with acoustofluidics for precise cell patterning, amplifies the scope of our exploration. As we navigate through these technological frontiers, the manuscript aims to unravel the complexities of multi-organoid systems and large-scale manufacturing techniques, spotlighting their potential impact on regenerative medicine and personalized therapeutic strategies.

With an emphasis on scalability, reproducibility, and real-time monitoring capabilities, this research sets out to define a holistic framework for advancing organoid engineering. Through an integrative approach, we envision a future where organoids, engineered with meticulous precision, serve as dynamic tools for unraveling the intricacies of human biology and as personalized therapeutic platforms tailored to individual patient profiles. As we embark on this scientific odyssey, our goal is to illuminate the path toward a future where the convergence of engineering and life sciences not only reshapes our understanding of disease but also redefines the landscape of personalized precision medicine.

2. Methodology

The research study begins with the careful selection of cell sources pertinent to the targeted organs or tissues, focusing on well-characterized cell lines to ensure subsequent compatibility with the proposed engineering approaches. Advanced culture media formulations are then employed to foster optimal growth, differentiation, and maturation of the organoids. Exploring various matrix substrates, including hydrogels and biomimetic scaffolds, aims to enhance the structural integrity and functionality of the developed organoids. Mechanobiological modulation follows, involving the application of controlled mechanical forces through techniques such as microfluidics or bioreactors to simulate physiological conditions.

This phase is accompanied by comprehensive characterization, utilizing advanced imaging techniques and biomechanical analyses to understand the organoids' responses to mechanobiological modulation. Subsequent stages involve the optimization of ultrasound parameters for selective piezo-channel activation and the integration of biosensors into acoustofluidic devices for precise cell patterning and real-time monitoring. Concurrently, the study delves into the development of interconnected multi-organoid systems, addressing challenges related to vascularization and communication between different organoid types. Scalable manufacturing protocols, incorporating bioreactor systems and automation, are explored for large-scale organoid production.

Rigorous structural and functional characterization, statistical analysis, and data integration across methodologies contribute to the validation of engineered organoids for personalized medicine applications. The research exploration concludes with a commitment to ethical standards, seeking

approvals and informed consent where applicable, ensuring the responsible and ethical conduct of research throughout the investigative study.

3. Background Research and Available Knowledge

3.1 Mechanobiology: The complexity of Mechanobiological Processes, Nuclear Mechanobiology and Embryogenesis with its associated Applications

Mechanobiology, situated at the crossroads of biology, engineering, chemistry, and physics, explores how physical forces and alterations in cellular and tissue mechanics influence development, cell differentiation, physiology, and disease. Human tissues experience mechanical forces during everyday activities such as joint movement, exercise, and blood circulation. The molecular mechanisms of mechanotransduction, wherein cells sense and respond to these forces, present a significant challenge and a key focus of the field. Contrary to the traditional genetic and biochemical disease models, mechanobiology posits that changes in cell mechanics, extracellular matrix structure, or mechanotransduction contribute to various diseases, including atherosclerosis, fibrosis, and cancer [1,2]. Skin fibroblasts and chondrocytes, key players in development and tissue maintenance, exemplify how mechanical cues influence cellular behavior. Fibroblasts respond to tension, compression, and shear pressure, synthesizing vital structural proteins and factors involved in tissue maintenance and remodeling. Chondrocytes, found in articular cartilage, deform in response to compressive loads, showcasing the biphasic nature of the tissue. Mechanical responsiveness is essential for joint development and maintenance, as both insufficient and excessive mechanical loading can lead to degeneration or atrophy. Nuclear mechanobiology reveals the responsiveness of the cell nucleus to mechanical signals relayed through the cytoskeleton. The nucleus undergoes changes in response to osmotic challenges, mechanical stretching, and compression, showcasing its dynamic response to mechanical stimuli. Additionally, mechanobiology plays a crucial role in embryogenesis, challenging the previous belief that only chemical signals regulate spatial changes in cell growth and differentiation. Mechanical forces generated within cells contribute to selfassembly during embryonic development, influencing spindle positioning, tissue patterning, and gene expression [3,4]. Applications of mechanobiology extend to clinical practices, where physical forces are leveraged for therapeutic purposes. Mechanical therapies, such as the use of pulmonary surfactant in premature infants or tissue expanders in reconstructive surgery, highlight the importance of understanding the mechanical basis of tissue regulation. Insights from mechanobiology hold promise for the development of improved medical devices, biomaterials, and engineered tissues, offering novel approaches to tissue repair and reconstruction. In essence, mechanobiology opens new avenues for understanding and manipulating the mechanical aspects of cellular and tissue functions, revolutionizing our approach to health and disease [5].

3.2 Therapeutic Ultrasound: Effects and Categorization, Transcranial Pulsed Ultrasound (TPU) with its developments and deployments

Therapeutic ultrasound, introduced in the 1950s, encompasses a variety of applications aimed at leveraging ultrasound for therapeutic benefits. These applications range from established practices like lithotripsy for breaking up kidney stones to emerging technologies such as targeted ultrasound drug delivery and high-intensity focused ultrasound (HIFU). The ultrasound utilized in these therapies, whether focused or unfocused, operates at frequencies between 800,000 Hz and 20,000,000 Hz, beyond the range of human hearing. The medical uses of therapeutic ultrasound are diverse. High-powered ultrasound can break up stony deposits, accelerate drug effects in targeted areas, measure tissue elasticity, and aid in cell or particle sorting for research purposes. Focused

ultrasound is employed for procedures like lithotripsy, cataract treatment, and non-invasive tumor ablation using High Intensity Focused Ultrasound (HIFU).

Acoustic targeted drug delivery (ATDD) utilizes ultrasound to enhance drug uptake in tissues, presenting a promising avenue for chemotherapy and other therapeutic interventions [6,7]. The effects of therapeutic ultrasound can be categorized into thermal and non-thermal effects. Thermal effects arise from sound wave absorption, while non-thermal effects involve phenomena like cavitation, microstreaming, and acoustic streaming. These effects contribute to increased blood flow, reduced pain and swelling, and the gentle massage of tissues, promoting cell repair through the inflammatory response [8,9]. In the realm of physical therapy, therapeutic ultrasound finds applications in conditions like ligament sprains, muscle strains, and joint inflammation. While evidence supports its effectiveness in conditions such as arthritis pain and musculoskeletal injuries, its utility for low back pain remains inconclusive. The application of therapeutic ultrasound is evolving, with ongoing research exploring its potential in diverse areas, from regenerative medicine to disruption of the blood-brain barrier for drug delivery. Despite its historical roots in the 1950s, therapeutic ultrasound continues to be an evolving field, with ongoing research exploring new applications, refining existing techniques, and deepening our understanding of its physiological effects [10]. Transcranial Pulsed Ultrasound (TPU) is an innovative approach to neuromodulation that employs low-intensity, low-frequency ultrasound to stimulate the brain. Originating from Dr. Alexander Bystritsky's proposal in 2002, further development led by Dr. William Tyler and his research team at Arizona State University has demonstrated therapeutic benefits without the invasive risks associated with surgeries like deep brain stimulation. TPU stands out as a noninvasive, focused procedure capable of manipulating brain waves externally, eliminating the need for implanted electrodes that may damage nervous tissue. Although a relatively young science, TPU holds significant potential for diverse applications, particularly in medical and military fields. Research efforts as of 2010 primarily focused on TPU's potential in treating neural disorders and enhancing cognitive function. Dr. Tyler's investigations extended to exploring TPU's ability to halt seizures in 2012. Ongoing studies involve testing TPU on various mammals, including humans, monkeys, and mice, to positively impact conditions such as epilepsy, Parkinson's disease, chronic pain, coma, dystonia, psychoses, and depression. Continued research into the safety and efficacy of TPU is expected to accelerate its integration into standard medical practice. In the military domain, the Defense Advanced Research Projects Agency (DARPA) is conducting research to develop a TPUpowered helmet aimed at controlling the mental stress of soldiers. This technology could precisely target specific brain areas with sound waves to stimulate activity without causing damage to surrounding regions, potentially moderating stress and anxiety levels. A prototype of this device is under development to enhance its capabilities and potential for military applications. The testing of TPU involves a distinctive approach, utilizing a lower frequency (about 5.7 MHz) compared to conventional ultrasound for anatomical analysis. This sub-thermal exposure allows for the manipulation of excitable tissue without detectable damage. Focused TPU on specific brain regions has demonstrated the ability to alter behavior, cellular electrophysiology, and synaptic plasticity in animals, showcasing its potential for high-level cognitive control [11,12].

Despite these promising aspects, TPU is still in the early stages of development, with ongoing clinical trials aiming to assess potential long-term side effects and safety considerations. In terms of therapeutic benefits, low-intensity, low-frequency ultrasound (LILFU) used in TPU presents advantages such as lower absorption in tissue, greater penetration depth, stronger particle deflections, improved acoustic penetration and power in bone, significant influence in kinetic effects, immediate and persistent effects, and a higher degree of patient safety compared to high-frequency

ultrasound. The method holds promise as a safer alternative to traditional surgeries, offering a novel avenue for precise and noninvasive neuromodulation [13].

3.3 The Organ-on-a-Chip (OOC) Technology Perspective with its associated Applications and Microfluidic Systems in terms of Biomedical Research

Organ-on-a-Chip (OOC) technology stands at the forefront of biomedical engineering, featuring multi-channel 3-D microfluidic cell cultures that replicate the activities and physiology of complete organs. This innovative approach, situated within the realm of bio-MEMS, offers a sophisticated in vitro alternative for drug development and toxin testing, surpassing the limitations of animal models. With applications spanning various organs like the brain, lung, heart, kidney, and more, OOCs address challenges by incorporating microfabrication and 3D cell-culture models, providing a nuanced understanding of complex physiological responses. Notably, these devices contribute significantly to disease studies, drug development, and toxicology research. Whether modeling brain disorders, replicating the gut microenvironment, mimicking pulmonary responses, or studying cardiac and renal functions, OOCs emerge as transformative tools in reshaping biomedical research and healthcare practices. Despite ongoing challenges, the technology's potential implications are vast, promising ethical alternatives for experimental models and revolutionizing the future landscape of personalized medicine and regenerative therapies. Organ-on-a-Chip (OOC) technology is revolutionizing biomedical research by providing a sophisticated platform to replicate organ functions in vitro. One notable application is the Liver-on-a-Chip, which mimics hepatic lobules using microfluidic techniques. It proves valuable in drug development, especially for predicting drug-induced liver injury, and offers a cost-effective model for studying liver dysfunction and pathogenesis. Liver-on-a-Chip devices are often made of materials like poly(dimethylsiloxane) (PDMS) but may use alternative materials like polysulfone or polycarbonate to avoid issues with molecule absorption. Studies highlight their potential in high-throughput toxicity studies, showcasing the viability of these devices in pharmaceutical workflows. Prostate-on-a-Chip focuses on recreating the prostate epithelium to understand cancer metastasis. Microfluidic systems, particularly those using PDMS, offer adjustable topography, gas and liquid exchange, and ease of observation [14,15,16]. Researchers, such as those at the University of Grenoble Alpes, use cylindrical microchannels to mimic human secretory ducts. These models aid in collecting prostatic fluid, studying cellular reactions to microenvironmental changes, and assessing drug candidates for treating metastasis scenarios. Blood Vessel-on-a-Chip addresses cardiovascular diseases by simulating the biological response of arteries. Unlike traditional methods like pressure myography, an artery-on-a-chip provides a scalable, inexpensive, and possibly automated platform. It enables the study of resistance artery malfunctions and allows for the assessment of a patient's microvascular status in personalized medicine. This innovative design controls and simulates heterogeneous spatiotemporal influences in the microenvironment, offering insights into the mechanical and chemical stimuli on smooth muscle and endothelial cells. Skin-on-a-Chip applications include testing topical pharmaceuticals, studying skin diseases, and creating noninvasive assays [17,18]. Challenges include collagen scaffolding detachment and incomplete cellular differentiation. Researchers address these issues by exploring various scaffolding materials, such as fibrin-based dermal matrix. Skin-on-a-Chip models demonstrate improved cell viability, differentiation, and growth compared to traditional static cultures, emphasizing the importance of dynamic perfusion. Endometrium modeling focuses on its role in implantation and pregnancy stages, contributing to reproductive research. Human-on-a-Chip endeavors aim to create multi-channel 3D microfluidic cell culture systems that replicate multiple organs. Such integrated systems, like the microfluidic humanon-a-chip, offer a realistic in vitro pharmacokinetic model, fostering advancements in drug development. These models allow researchers to measure the direct effects of one organ's reaction on another, contributing to a more holistic understanding of systemic drug responses [19,20].

The use of organ-on-a-chip technologies also holds promise in replacing animal testing in drug development. These biomimetic microfluidic systems provide a more affordable and controllable alternative to lengthy, expensive, and controversial animal experiments. The development of physiologically based perfusion in vitro systems enhances the reliability of drug testing, with multi-compartment microfluidic devices mimicking the mass transfer of compounds in compartmental models of the human body. As these technologies advance, they offer a potential solution to the challenges posed by current isolation of organs, opening new possibilities for drug development, toxicology research, and personalized medicine. Microfluidics is a multidisciplinary field that involves manipulating small amounts of fluids in the range of 10^(-9) to 10^(-18) liters using channels with sizes ranging from tens to hundreds of micrometers. It has practical applications in molecular analysis, molecular biology, and microelectronics, enabling the design of systems for multiplexing, automation, and high-throughput screening. The technology has been employed in various applications such as inkjet printheads, DNA chips, lab-on-a-chip technology, micro-propulsion, and micro-thermal technologies since its emergence in the early 1980s.

Microfluidic systems can be characterized by small volumes, sizes, low energy consumption, and microdomain effects. They transport, mix, separate, or process fluids, and the behavior of fluids at the microscale is influenced by factors like surface tension, energy dissipation, and fluidic resistance. The microscale behavior often results in laminar flow rather than turbulent flow, affecting the mixing of co-flowing fluids. High specificity of chemical and physical properties can be achieved at small scales, leading to more uniform reaction conditions and higher-grade products [21,22]. There are different types of microfluidic flows, including open microfluidics where at least one boundary is removed, continuous-flow microfluidics relying on steady-state liquid flow through narrow channels, droplet-based microfluidics manipulating discrete volumes of fluids, digital microfluidics using electrowetting for droplet manipulation, and paper-based microfluidics for portable and userfriendly medical diagnostic systems. Particle detection in microfluidics has seen significant development, with microfluidic resistive pulse sensing (MRPS) offering advantages in detecting and sizing small fluid-borne particles. Microfluidic-assisted magnetophoresis, another application, is used for the separation and sorting of different fluids or cell types. It involves integrating microfluidic devices with magnetophoresis, utilizing magnetic fields to separate magnetically active substances and facilitating efficient mixing within microdroplets or plugs. The technology has diverse applications, including industrial purification processes and research-oriented cell separation techniques [23]. Microfluidics, a cutting-edge technology, finds applications across various fields, notably in microsystems for handling off-chip fluids and on-chip manipulation of nanoliter and picoliter volumes. The inkjet printhead is a successful commercial application of microfluidics. In the medical field, microfluidics has revolutionized molecular biology procedures, enabling advancements in enzymatic analysis, DNA analysis, proteomics, and chemical synthesis. Biochips, with integrated operations like detection and sample preparation, are emerging in clinical pathology for immediate point-of-care disease diagnosis and in continuous monitoring for biochemical toxins. Microfluidic technology has empowered biologists to control the cellular environment for singlecell studies, cellular aging, microenvironmental control, and precise concentration gradients. It has applications in force measurements, electric field integration, plant on a chip, and antibiotic resistance testing. DNA chips, based on microarrays, have paved the way for advancements in molecular biology, including two-dimensional electrophoresis, transcriptome analysis, and PCR amplification. The integration of microfluidics and optics, known as optofluidics, has led to the development of devices such as tunable microlens arrays and optofluidic microscopes, enhancing capabilities like fast sample throughput and automated imaging.

Photonics Lab on a Chip (PhLOC) is becoming popular for analyzing actinides and nitrates in spent nuclear waste, offering flexibility, safety, and lower analyte usage. High-Performance Liquid Chromatography (HPLC) in microfluidics has evolved, with integrated columns offering advantages in terms of form factor, material versatility, and applications in drug analysis. Acoustic droplet ejection (ADE) is a gentle technology using ultrasound for fluid transfer, suitable for applications in proteomics and cell-based assays. Microfluidic fuel cells utilize laminar flow to control the interaction of fuel and oxidant. In astrobiology, microfluidic devices play a crucial role in measuring the chemical composition of extraplanetary bodies, aiding the search for extraterrestrial life. Food science benefits from microfluidic techniques like droplet microfluidics and lab-on-a-chip for research in nutrition, food processing, and safety. Looking to the future, microfluidics holds promise for personalized cancer treatment, offering sensitive detection, higher throughput, and reduced time and costs. It enables the prediction of drug responses based on biomarkers and facilitates the analysis of circulating tumor cells and tumor-derived materials. Microfluidic devices can simulate the tumor microenvironment for testing anticancer drugs and exploring the tumor heterogeneity through the advanced techniques like single-cell chromatin immunoprecipitation sequencing in droplets [24,25]. Regenerative medicine is a field focused on replacing, engineering, or regenerating human or animal cells, tissues, or organs to restore normal function. The primary goal is to stimulate the body's repair mechanisms to heal irreparable tissues or organs. This approach holds the promise of addressing the shortage of organs available for donation, particularly when cells are derived from the patient's own tissues, minimizing the risk of organ transplant rejection. Historically, the concept of regenerating body parts dates back to ancient Greece. The field evolved with advancements in transplanting body parts in the 20th century, leading to tissue engineering and the subsequent emergence of regenerative medicine [26].

Stem cells play a crucial role in various regenerative approaches, such as cell therapies, immunomodulation therapy, and tissue engineering. The term "regenerative medicine" was coined in 1992, gaining popularity in 1999 when William A. Haseltine described interventions aiming to restore normal function damaged by disease, trauma, or aging. Stem cell research has been a focal point, with the isolation of human embryonic stem cells and embryonic germ cells marking a significant milestone in the late 1990s. Research in regenerative medicine has led to notable breakthroughs, including the first tissue-engineered trachea transplantation in 2008 and the transplantation of retinal pigment epithelium cells derived from induced pluripotent stem cells (iPS cells) in 2014. However, controversies surrounding falsified test results and ethical concerns, such as those involving Paolo Macchiarini, have underscored challenges in the field. In dentistry, regenerative medicine explores ways to repair damaged teeth, potentially regrowing dentin—the layer beneath enamel. Researchers have developed drugs like Tideglusib and explored stem cells from baby teeth for dental pulp regeneration, showcasing potential alternatives to traditional dental procedures [27]. The importance of mechanical cues in the metastatic environment—such as matrix stiffness, topography, mechanical stresses, and cellular deformation—in influencing tumour development and propagation has been emphasized by researchers during the past ten years. Understanding these environmental influences' cellular and molecular underpinnings and precisely adjusting the mechanistic responses of cancer cells to them could lead to the discovery of novel therapeutic approaches. This manuscript explores how mechanical cues play a critical role in the tumor microenvironment, which controls the development and spread of cancer. Furthermore, it clarifies recently developed concepts about mechanosensing and mechanotransduction pathways that link cellular reactions, including gene expression, to phenotypic changes brought on by outside interventions. [28].

Notable advancements in biomaterials have made it possible to design intricate systems with changeable characteristics. Biomaterials can be tailored in their physical, chemical, and biological properties to provide particular cues for cells and applications. Scaffolds can be reduced in size to cellular dimensions, and these cues can be accurately designed in space. The combination of stimuli-responsive systems and nanotechnology has produced multifunctional materials, such as active biomaterials whose properties may be controlled externally in both space and time. These substances have the potential to be highly influential in biomedical research [29].

Extracellular matrix materials, including fish skin with omega-3, have found applications in reconstructive surgery and treatment of chronic wounds. Cord blood, although primarily used for blood and immunological disorders, has been studied for potential applications in diabetes and other diseases. Wharton's jelly and cord lining are explored as sources for mesenchymal stem cells, showing promise in various clinical trials for cardiovascular diseases, neurological deficits, and more. Despite ongoing research and promising developments, challenges remain, emphasizing the need for continued exploration and ethical considerations in regenerative medicine [30,31].

Mechanotransduction in mammalian cells may be investigated using novel approaches provided by active biomaterials. These materials provide exogenous stresses to cells in a controlled temporal way or dynamically modify their resistance to endogenous forces. These materials transform external signals into changes in matrix elasticity or forces at the cell-material interface by stimuli-responsive components such as molecules, polymers, and nanoparticles inside cytocompatibility biopolymer networks. The use of active biomaterials in mechanobiology has provided new understandings and treatment options for diseases such as tissue regeneration, fibrosis, and cancer metastasis. The many cellular responses that may be investigated using these platforms are summarized for future directions. These reactions also include cell migration, differentiation, nuclear translocation of mechanosensitive transcriptional regulators, cytoskeletal organization, and receptor signaling. The significance of recent developments in active biomaterials for the future is emphasized [32,33].

4. The Bioengineering Approaches for Advanced Organoid Research

Recent breakthroughs in 3D cell culture technology have revolutionized the creation of organoids derived from stem cells, offering a remarkable replication of both the structural and functional aspects of native organs. The current trajectory of organoid technologies is geared towards uncovering the fundamental factors that govern the intricate processes involved in organoid development. This exploration encompasses not only the impact of physical cues but also delves into the realm of biochemical signaling. Scientists are increasingly focused on engineering dynamic niches that closely mimic in vivo organogenesis conditions, aiming to produce organoids with enhanced reproducibility and reliability for a myriad of applications. To meet the growing demand for more sophisticated organoid cultures, innovative approaches rooted in biomaterials and advanced engineering techniques are being integrated into conventional methods. These novel strategies aim to augment organoid research by providing a platform for more nuanced control over the developmental processes. Notably, recent strides in organoid engineering encompass aspects such as extracellular matrices and genetic modulation, and these advancements are meticulously summarized to highlight the crucial parameters essential for achieving organ-specific patterning. Furthermore, the evolution of organoid engineering extends beyond current capabilities, exploring avenues for creating tunable organoids that can respond dynamically to both exogenous and

endogenous cues. This adaptability holds significant promise for advancing developmental studies, disease modeling, and therapeutic applications.

As researchers delve into these next-generation approaches, the perspective trends in organoid engineering are poised to shape the future landscape of scientific inquiry, opening up new horizons for understanding organ development, modeling diseases, and developing targeted therapeutics. To provide an idea and a better understanding regarding this aspect figure 1 provides an illustrative visualization concerning the matter.




Figure 1. An Illustrative Visualization concerning Advanced Organoid Research

5. The Advancing Frontiers within Tissue Engineering

Biomaterials serve as the foundation for creating scaffolds that mimic the natural extracellular matrix (ECM), providing structural support for cell adhesion, proliferation, and differentiation. Synthetic polymers, ceramics, and metals were defined as key biomaterial categories. The advent of biodegradable polymers, such as poly (lactic-co-glycolic acid) (PLGA), marked a significant advancement, enabling scaffolds that support tissue growth and eventually degrade as new tissue forms.

Additionally, the importance of surface modifications, porosity, and mechanical properties in biomaterial design for specific tissue engineering applications became emphasized. Bio ceramics, particularly bioactive glass ceramics, were selected for their suitability in bone tissue engineering due to bioactivity and osteoconductivity. The incorporation of ceramics into composites, especially with polymers, addressed challenges such as brittleness.

Ceramic-polymer composites, including those with bioactive glass, demonstrated improved strength and bioactivity. Metals, traditionally limited in tissue engineering due to non-biodegradability, saw progress with the emergence of biodegradable metal alloys like magnesium-based alloys. Their mechanical properties make them suitable for structural support, and ongoing research aims to optimize their corrosion behavior.

The section area of interest concluded with an exploration of stem cells, emphasizing their potential in tissue engineering, with a focus on adipose-derived stem cells, induced pluripotent stem cells, and the application of multipotent stem cells in cartilage tissue engineering. The immunomodulatory properties of stem cells and their role in personalized therapeutics were also explored to provide a better overview of the retrospective. To better understand figure 2 will provide an insight into the matter.




Figure 2. The Advances within Tissue Engineering

6. Stem Cells Therapy: An Investigative Exploration of a Case Study Analysis

Stem-cell therapy involves utilizing stem cells to treat or prevent diseases or conditions. As of 2016, the most established form of stem-cell therapy is hematopoietic stem cell transplantation, commonly in the form of bone marrow transplantation or using cells derived from umbilical cord blood.

Ongoing research explores diverse stem cell sources and their application in treating neurodegenerative diseases, diabetes, and heart disease. The field has encountered controversy, particularly regarding embryonic stem cells, their isolation, and applications, often intertwined with abortion politics and human cloning concerns.

Additionally, marketing treatments based on transplanting stored umbilical cord blood has sparked debates. Hematopoietic stem cell transplantation has been a longstanding practice for treating conditions like leukemia and lymphoma. Another therapy, Prococvhymal, utilizes mesenchymal stem cells and was conditionally approved in Canada for managing acute graft-vs-host disease in children.

Research investigates stem cells' potential in various areas, including neurodegeneration, brain and spinal cord injuries, frailty syndrome, heart diseases, and regrowing tissues like teeth and cochlear hair cells. Clinical trials explore the efficacy of stem-cell therapies in different medical applications. Despite advancements, criticisms and challenges exist. Studies on bone-marrow stem cells' effects on ventricular function have faced discrepancies, and meta-analyses have questioned the reported benefits of stem cell therapy for heart disease.

Ethical concerns, especially related to embryonic stem cells, and the need for precise matches in transplantation treatments are ongoing issues. Stem-cell therapy extends into drug discovery, biomedical research, and conservation efforts. Researchers are exploring the potential of stem cells in drug testing, and the advent of induced pluripotent stem cells (iPSCs) offers possibilities for treatments in endangered animals. Stem cells are primarily isolated from bone marrow or adipose tissue for regenerative therapy.

Mesenchymal stem cells, with diverse differentiation abilities, are widely studied, and ongoing research explores new sources like skin, dermis, and extra-embryonic mesenchymal stem cells. Controversy surrounds the use of human embryonic stem cells, often due to ethical and religious objections. Clinical trials involving embryonic stem cells, like the GRNOPC1 trial for spinal cord injury, have faced challenges and discontinuations.

Stem-cell therapy holds promise for treating various medical conditions, but challenges include ethical concerns, controversies, and the need for more extensive clinical evidence to establish its efficacy in specific applications.

Ongoing research aims to address these challenges and unlock the full potential of stem cells in regenerative medicine. Figure 3 provides a graphical overview concerning the matter. Stem cell therapy has emerged as a medical approach utilizing stem cells to treat or prevent various diseases and conditions. The primary established therapy involves hematopoietic stem cell transplantation, commonly in the form of bone marrow transplantation or from umbilical cord blood.

Research is ongoing to explore different stem cell sources and their applications in treating neurodegenerative diseases, diabetes, heart disease, and other conditions. Hematopoietic stem cell transplantation has been a widely practiced form of stem-cell therapy for over 90 years, particularly in treating conditions such as leukemia and lymphoma.

The therapy aims to reverse the side effects of conventional chemotherapy by reintroducing healthy bone marrow stem cells from a donor. Other stem-cell therapies, like Prococvhymal, have been conditionally approved for managing conditions such as acute graft-vs-host disease in children.

Research is actively exploring the potential of stem cells in treating various diseases, with a focus on neurodegenerative disorders like Parkinson's and Alzheimer's. Stem cell expansion methods, including two-dimensional and three-dimensional cell culture, play a crucial role in generating sufficient high-quality stem cells for research and treatment. Stem cells are being investigated for their applications in treating heart disease, particularly myocardial infarction.

However, clinical trials have shown mixed results, and some studies have raised criticisms regarding discrepancies and methodological issues in reporting the outcomes of stem cell therapy for heart-related conditions. Beyond cardiac issues, stem cells are studied for their regenerative potential in diverse areas such as wound healing, regrowing teeth, cochlear hair cell regrowth, and vision impairment. Mesenchymal stem cells, in particular, are explored for orthopedic applications, including bone and muscle trauma, cartilage repair, and disorders like osteoarthritis.

In the veterinary field, stem cell treatments have been developed for animals, targeting conditions such as myocardial infarction, stroke, tendon and ligament damage, osteoarthritis, and more. The high frequency and severity of injuries in racehorses have put veterinary medicine at the forefront of stem cell therapy development.

Despite the promising potential, controversies and criticisms surround stem cell therapy, especially concerning human embryonic stem cells. The ethical concerns and regulatory issues have sparked debates. Moreover, the proliferation of stem cell clinics, often making unsubstantiated health claims and lacking regulatory approval, has raised concerns about patient safety and proper scientific validation.

In recent years, there has been an increasing trend in stem cell tourism, where clinics in developing countries offer stem cell therapies on a medical tourism model. Regulatory bodies, such as the FDA, have issued warnings and taken legal actions against some clinics for marketing unproven stem cell treatments. The COVID-19 pandemic saw some stem cell clinics attempting to market unproven stem cell and exosome treatments for the disease.

Regulatory agencies, including the FDA and FTC, took swift action against such marketing, emphasizing the lack of approved stem cell treatments for COVID-19 and the importance of evidence-based practices in medicine.




Figure 3. The Potential Uses of Stem Cells

7. Tumor Growth and Proliferation: An Investigative Case Study Analysis

Cancer cells undergo metastasis when they travel long distances via the lymphatic or circulatory systems. The focus on particular secondary organs, guided by the "seed and soil hypothesis" and the "mechanical hypothesis." The behavior of cancer cells is greatly influenced by the mechanical signals provided by the microenvironment, such as stretching, topography, and matrix stiffness. This investigation also looks at contemporary technical developments, the conversion of mechanical signals into biochemical reactions, and how these cues control the progression of cancer. Comprehending these factors is essential for prospective uses in mechanomedicine to cure cancer.

There are various types of Mechanisms which controls all the governing towards the growth of cancer. Breast cancer patients who have increased mammary matrix stiffness and density, which is linked to lysyl oxidase-induced collagen cross-linking, have a 4–6 times higher risk of breast tumor development. Soft matrices stop the growth of healthy cells and is the principal cause of the transformed and normal fibroblasts to undergo apoptosis; nevertheless, altered cells are insensitive and continue to proliferate uncontrollably.

Tumor cells proliferate more on matrices that resemble the stiffness of target organs for metastasis, demonstrating tissue tropism. The contractility of actomyosin, particularly on pliable substrates, influences tissue tropism. Cancer cell lines are categorized as "rigidity-dependent" (like MDA-MB-231) or "rigidity-independent" (like PC-3) depending on how they react to substrate rigidity. To control this response, cellular contractility is essential. Nevertheless, a lot of rigidity-sensing research ignores the possible influence of soluble substances from stromal cells within the tumor microenvironment. Future research requires aiming to gain a more thorough knowledge of in vivo complexity and also should consider both mechanical and biological inputs. Tumor-associated collagen signature (TACS) is a dynamic alteration in the topography and organization of collagen extracellular matrix (ECM) fibers in breast tissue that occurs during the course of metastasis.

Collagen fibers are randomly distributed in a healthy state (TACS-1), but they align parallelly during tumor progression (TACS-3), which promotes breast cancer cell migration away from the original tumor.

Recent research work presents mechanically-induced dormancy, in which actomyosin contractility is activated to inhibit the growth of noncancerous breast epithelial cells (MCF-10A) using anisotropic cues from aligned collagen fibers. Malignant breast cancer cells, such as MDA-MB-231 and MCF-7, continue to proliferate unchecked despite these inhibitory stimuli.

Some breast cancer cells are not greatly affected by topographic features like gratings and square pits, presumably because they are less sensitive to big structures. In order to facilitate mechanicallyinduced dormancy through depth sensing, topographic features with micrometry-scale pits (micropits) that imitate the physiological porous microenvironment were mainly used to study bone, a primary source of breast cancer metastasis. Different hemispherical aspects of lung cancer cell proliferation on Nano topography surfaces indicate a nuanced response.

Cancer cells distort through tiny holes during invasion through dense matrices, and their nucleus a big organelle—can restrict the rate of invasion and experience considerable distortion. Micropillar topographies showed that whereas cervical cancer cells (HeLa) showed no change in proliferation, healthy cells did. This difference may have resulted from variations in nuclear lamina and lamin A/C expression. It is of interest to look into how the cytoskeletal network and cell surface receptors translate these mechanical cues and reduce proliferation in healthy cells but not in cancerous cells.

Though most in vitro research has concentrated on distinct surface characteristics, future investigations ought to further investigate how the intricate variety of matrix architecture influences cell behavior regulation. Anomalous lymphatic circulation and tumor vasculature are the reasons behind elevated tumor interstitial fluid pressure in solid tumors. The cancer cells' compressive forces and the elevated pressure may cause the tumor cortex to permanently stretch mechanically. The interstitial fluid pressure causes mechanical stretching, which promotes the growth of cancer cells.

For example, six hours of static stretching at applied air pressure activates YAP/TAZ, allowing contact-inhibited human mammary epithelial cells to reenter the cell cycle in the S-phase. The work emphasizes how local YAP/TAZ activity is regulated by mechanical forces. F-actin-capping and severing proteins inhibit YAP/TAZ in contact-inhibited cells at low mechanical stress zones.

On the other hand, actomyosin contractility controls YAP/TAZ-mediated proliferation in cells at the boundaries of the same multicellular sheet. By stimulating YAP/TAZ and encouraging their nuclear translocation, this mechanical stretching can overcome growth arrest brought on by contact inhibition, starting tumor development and multiplication.

The processing concerning this matter is represented within figure 4 for a better visual illustration. The idea of mechanically-induced dormancy—where topographic cues first stop cell growth but eventually cause cells to become resistant to these signals—is introduced by the temporal response of cells to matrix mechanics. Knowing the molecular processes behind this resistance may help identify therapeutic targets for cancer cells that want to undergo apoptosis and prolonged dormancy. Research findings indicates that unique roles in mechanoregulation are suggested by the varying rates of transcriptional regulator translocation in response to cyclic stretching. It is an interesting concept to investigate if cells that are separated from platforms and transfused into animal models exhibit a mechanical memory response. This process may involve epigenetic alterations, such as chromatin remodeling and histone modifications.




Figure 4. An illustration of the Tumor Growth and Proliferation Process

8. ECM Mechanosensing and External Forces

The biomechanical qualities of the extracellular matrix (ECM), such as stiffness, viscoelasticity, and topography, have a substantial impact on cell behavior. Through focal adhesion complexes, cells are able to detect surface stiffness, which informs the nucleus and influences cellular responses. In 2D cell culture, the culture vessels' elastic modulus affects the migration, self-renewal, and differentiation of the cells. Differentiation of stem cells is guided by ECM stiffness that resembles particular tissues. Diseases like fibrosis and cancer are linked to increased ECM stiffness. Hydrogels are widely utilized, especially Matrigel, although there are issues with their variable composition. It is imperative to transition into specified hydrogels and standardized media compositions. Shear stress and traction force are two examples of external mechanical stimuli that are important for stem cell differentiation and organoid growth during organogenesis. Fundamental mechanisms that affect cell shape, organization, and behavior in response to external stimuli include mechanotransduction and mechanosensory.

Organoid's sense mechanical stimuli by a complex interaction of proteins that react to various stimuli, such as those in mechanosensitive channels, focal adhesions, and cell-cell communication. For location information, force transmission across scales is probably crucial. Mechanical restrictions may appear during morphogenesis and affect cellular polarity. Tissue remodeling is facilitated by coordinated polarity and collective cell migration. Microtubules are involved in behavior coordination and the preservation of cell shape. Epithelial morphogenesis is influenced by apico-basal forces, which are associated with the actomyosin nucleus and structure. Cytogenesis dynamics are influenced by the ability of cell-to-cell contact topology to distinguish between mechanical equilibrium and non-equilibrium states. Close to equilibrium states that are organized are linked to healthy tissue development. During morphogenesis, cell-cell communication improves collective awareness of weak gradients, highlighting the significance of communication in detecting and reacting to mechanical stimuli during organoid formation. The control of biochemical, mechanical, and chemical stimuli during organoid formation is crucial, but understanding the orchestrated effects of these mechanisms is challenging.

Undesirable changes in stem cells may occur unpredictably. In silico organoid models offer a powerful tool to enhance understanding, develop therapeutic strategies efficiently, and optimize experimental designs. These models can predict organoid growth, cell differentiation, and functionality, providing insights into the effects of various manipulations. While limited studies have been conducted, such as modeling oxygen transport and growth inhibitory signals, the development of in silico organoid models is expected to progress rapidly, paralleling advancements in in vitro organoid studies and offering valuable insights into organogenesis, tumor development, progression, and treatment responses. Organoids, which simulate tissue self-organization during embryogenesis, are useful tools for drug discovery, disease modelling, and personalized medicine.

Organoids allow for the investigation of the impact of certain biochemical and physical stimuli on tissue formation and regeneration, despite the disparities between in vivo and in vitro settings. An issue that needs more research is the relationship between molecular signaling pathways and external/internal mechanical stresses during organogenesis and embryogenesis. It is difficult to design a well-controlled culture system that yields repeatable results while maintaining the ability to self-organize, however new technologies such as bioprinting, 3D printing, microfabrication, and dynamic systems present prospects for advancement. To better understand figure 5 provides a visual representation relating to the matter.




Figure 5. The visual representation of ECM Mechanosensing with External Forces

9. Active Biomaterial Systems Analysis

Active materials offer an ideal platform for investigating mechanotransduction in mammalian cells, where cells sense and respond to mechanical signals in their microenvironment. This process involves dynamic adhesions, cellular forces, and responses to both endogenous and exogenous forces. The mechanical interplay between cells and their surroundings is intricately regulated at various length scales. Active biomaterials, capable of converting electromagnetic fields and sound waves into mechanical cues, provide a means to replicate the dynamic microenvironment in living tissues by altering mechanical properties or generating/transmitting forces.

Hydrogel-based synthetic substrates have significantly advanced the understanding of how cells respond to their extracellular matrix (ECM) through both endogenous and exogenous forces. These studies demonstrate that alterations in physical interactions with the ECM, such as matrix stiffness, can drive key biological processes, including migration and stem cell differentiation. Mechanically active materials and techniques like micropipette aspiration and atomic force microscopy have revealed the force-sensing molecular machinery involved in mechanotransduction, with integrins, adaptor proteins, and transcriptional regulators like YAP and TAZ playing crucial roles.

Additionally, mechanosensitive ion channels, exemplified by Piezo2, act as regulators of focal adhesion and stress fiber formation. Temporal variations in endogenous pressures and foreign stresses elicit diverse mechanoresponses in vitro. In reaction to the softening or stiffening of the matrix, cells, such as myoblasts and fibroblasts, display morphological alterations and focal adhesion dynamics. The nuclear translocation of mechanosensitive regulators such as NFAT and YAP/TAZ is preceded by changes in the cytoskeleton. These reactions exhibit memory effects and are sensitive to the timing of stimulus.

Different responses are shown by cardiac fibroblasts and muscle myoblasts depending on the initial matrix conditions. hMSCs have mechanical memory, which affects the results of differentiation. When it comes to myofibroblast activation and MSC differentiation, the timing of mechanical dosing is critical since it determines long-term cell behavior. After isolation, cells can require a period of recuperation, and active materials that allow for in situ mechanotransduction observations are ideal for examining temporal processes. Improved mechanical characterization, particularly in 3D systems, and attempts to disentangle force generation and matrix stiffness in external stress-applying biomaterials will be necessary for future strides in mechanobiology employing active biomaterials. Extensive research on force dissipation in active biomaterial matrices is necessary, necessitating customized techniques for stress measurement in live organisms. To provide an understanding and better visual scope figure 6 provides the visual representation concerning the matter of perspective.




Figure 6. A visual representation of Active Biomaterials System in terms of Applications

Active biomaterials provide hitherto unseen possibilities for mechanotransduction research because of their capacity to modulate exogenous forces or adjust resistance to endogenous stresses. With the ability to precisely adjust activation time and force parameters, photosensitive and magnetically triggered techniques have produced valuable information about how force intensity, frequency, and duration affect cellular responses. Therapeutics for tissue regeneration have showed potential with macroscale magnetic scaffolds. However, technologies such as 3D traction force microscopy are increasing stress mapping at cellular and subcellular levels, and a simplified calibration approach is required to evaluate mechanical loading caused by diverse methods. To manage stress distribution inside active biomaterials, cooperation across materials science, computational mechanics, and experimental biomechanics is essential.

With the emergence of new technologies, microfluidic systems, and machine learning, the field is anticipated to grow quickly. It will provide high-throughput methods for examining cell behavior as well as possible uses in pharmaceutical discovery and personalized therapy. The combination of active biomaterials and organoids has the potential to shed light on oncology and developmental biology and lead to the creation of successful treatments.

10. Organs-on-a-chip (OOC) Potentials for Organoids, Challenges and Directions

Organs-on-a-chip represent microfabricated cell culture devices designed to emulate the functional units of human organs in vitro. The design process involves a reductionist analysis of the target organ to identify key elements such as cell types, structural organization, and specific microenvironments. These devices are constructed using microfabrication techniques, such as soft lithography, and aim to replicate the identified features of the target organ. For instance, an organ-on-a-chip model of the lung's alveolar-capillary unit includes microchannels for coculturing alveolar epithelial cells and pulmonary microvascular endothelial cells separated by a thin, flexible membrane. Additionally, mechanical components can be integrated to simulate physiological conditions, such as breathinginduced cyclic mechanical stretch. Organs-on-a-chip have been applied in veterinary medicine, where they have been utilized to treat conditions like myocardial infarction, stroke, tendon and ligament damage, osteoarthritis, and more in animals like horses and dogs. These applications have shown promise in promoting tissue regeneration and reducing the re-injury rate. Stem cells, particularly mesenchymal stem cells, have been a focal point in these treatments, with successful outcomes demonstrated in bone repair, ligament and tendon repair, joint repair, muscle repair, and nervous system repair. The technology has expanded into the realm of organoids, which are threedimensional cell cultures that self-organize to mimic specific organs. Combining organs-on-a-chip with organoid technology addresses challenges such as controlling the microenvironment of organoids. For instance, microfluidic systems in organs-on-a-chip can generate stable morphogen gradients to precisely control biochemical microenvironments. Vascularization of organoids within the chip is explored to address nutrient supply issues, and mechanically active culture systems are employed to provide biomechanical cues for the structural and functional maturation of organoids.

These advancements open new possibilities for studying human physiology, disease processes, and drug responses in vitro, potentially reducing reliance on animal studies for preclinical assessments. However, challenges and limitations persist, and ongoing research aims to refine and enhance the capabilities of this innovative technology. Modeling tissue-tissue and multiorgan interactions is a crucial challenge in replicating the complexity of the human body in vitro. While organoids inherently mimic the cell types present in native organs, their ability to simulate dynamic interactions between different tissues is limited. To address this, researchers are turning to organoidon-a-chip technology to engineer environments that facilitate the coculture of diverse cell and tissue types. For example, a vascularized liver organoid-on-a-chip was developed, where a multicompartment microdevice enabled the growth of induced hepatic cells with human endothelial cells in a controlled environment. The continuous perfusion of media mimicked blood circulation, resulting in vascularized liver organoids with enhanced maturity and improved hepatic functions, showcasing the potential for tissue-tissue interaction modeling. Expanding on this approach, efforts are underway to create multiorgan models using microfluidic arrays. Researchers have demonstrated a multiorganoid model by coculturing stem cell-derived liver, intestinal, and stomach organoids in separate compartments connected by media flow. This innovative system allows communication between organoids, simulating bile acid homeostasis and revealing interorgan crosstalk.

This advancement opens up possibilities for more comprehensive in vitro platforms that can better capture the intricate interactions between different tissues within the body. Taking a step further, the development of multiorgan systems aims to simulate physiological interactions between different organs. A micro engineered heart-lung-liver model, for instance, combined 3D printed liver and heart organoids with micro engineered lung tissues. The interconnected culture modules allowed for the perfusion of a common media, enabling the study of complex interactions between the heart, lung, and liver. This system uncovered previously unknown cardiotoxicity of a chemotherapeutic drug, highlighting the potential of micro engineered multiorganoid systems for advanced preclinical drug screening. While further validation is needed, these developments underscore the promise of organoid-on-a-chip technology in advancing our understanding of human physiology and disease responses, ultimately reducing reliance on traditional animal studies in preclinical research. Reducing variability in organoid cultures, a significant challenge in organoid technology, is being addressed through innovative approaches, particularly in the realm of organoid-on-a-chip technology.

Organoids, despite their potential, exhibit substantial variability in size, structure, function, and gene expression. Microengineered systems offer a promising solution to this issue. Automated control of organoid culture is achieved through precise and dynamic handling of fluids and tissues at the biological length scales of organoids. An example is an electrowetting-based digital microfluidic platform that demonstrated automated culture of hepatic organoids, showcasing the potential for reproducibility in procedures requiring precise manipulation over extended periods. High-throughput manipulation and analysis of organoids further contribute to reducing variability. Microfluidic platforms with high-density arrays allow for the culture and analysis of organoids at increased density, enabling selection, manipulation, and screening in a more efficient manner. For instance, a microfluidic platform incorporated a high-density array of microfabricated pillars to immobilize and analyze intestinal organoids, providing tunable size-based selection and compatibility with more complex systems for enhanced homogeneity of organoid populations. Integration of biosensing elements into culture platforms represents another approach. Multiorgan-on-a-chip devices with label-free biosensors enable long-term monitoring of organoids.

A universal electrochemical immunobiosensing platform demonstrated multiplexed sensing, allowing continuous monitoring of specific targets during drug treatment. This biosensing capability holds promise for screening-based optimization of organoid culture conditions, contributing to minimizing variability in organoid cultures. These advanced organoid culture systems showcase the potential of organoid-on-a-chip technology in overcoming challenges associated with variability, thus enhancing the reliability and reproducibility of organoid-based studies for applications in disease modeling, drug screening, and transplantation.

11. An insight into the Limitations of current Organoid Systems

Current organoid systems, while demonstrating impressive physiological functionality in various organs like the intestine, stomach, liver, and mammary glands, still face significant limitations. Organoids often lack key specialized cell types and fail to fully replicate the complexity of native organs due to the absence of a mesenchymal compartment, vascularization, and microbiome. Challenges include achieving consistent cellular organization in multi-compartment organoids and addressing the technical difficulties in integrating features like flow, air interface, or mechanical stimuli for enhanced maturation.

The limited lifespan of organoids, typically around one week for epithelial organoids, poses a challenge, especially for patient-derived and pluripotent stem cell (PSC)-derived organoids, which often fail to mature beyond a fetal phenotype. Nutrient supply constraints and issues related to the inaccessibility of inner organoid compartments further contribute to this limitation. The growth of organoids to larger sizes leads to nutrient inaccessibility, necrosis in the inner core, and challenges in controlling different organoid compartments, hindering experimental manipulations and applications which are illustrated in figure 7.




Figure 7. A Visual Representation of current Organoid Systems and Approaches

Heterogeneity in organoid formation efficiency, end-point morphology, and function is another significant limitation. Variability, inherent to the stochastic nature of in vitro self-organization and cell fate choices, needs to be reduced for optimal use in disease modeling, drug screening, and regenerative medicine. Efforts to address this involve engineering strategies, such as automation, defined media and matrices, and precise live assessments.

However, the complexity of organoid generation protocols, particularly for PSC-derived organoids, remains a challenge to automation. Readouts in organoid systems primarily rely on optical monitoring, providing limited information about organoid functionality.

Challenges in assessing barrier integrity and functionality of hepatic systems highlight the need for improved readout methods. Integration of miniature biosensors into organoid systems is proposed to address this challenge, requiring adaptations in the culturing setup. Furthermore, high-throughput measurements for drug screening applications necessitate the implementation of automated functional measurements.

These inherent limitations in organoid systems call for a re-evaluation of their design principles. Engineering approaches, akin to organ-on-a-chip technologies, emerge as promising solutions to overcome these challenges.

The case analysis also provides engineering strategies at different scales, including (sub-)cellular behavior engineering, local tissue engineering within the niche, and holistic organism models. The exploration of new approaches for functional development readouts in organoids aims to enhance their characterization and integration into high-throughput assay pipelines.

12. Results and Findings


The integration of organoids with organs-on-a-chip technology represents a promising avenue to bridge the gap between current organoid capabilities and the complexity of human organ development and function. Researchers envision a future where these combined technologies mirror the intricate inner workings of human organs, providing easily accessible and controllable model systems. In drug discovery, organoids-on-a-chip offer a versatile approach, combining the target identification and validation strengths of organoids with the reproducibility and controllability of organs-on-a-chip for more predictive preclinical models. Personalized medicine could benefit significantly from organoids-on-a-chip, creating patient- and population-specific disease models. Micro engineered devices enable the recreation of disease-specific culture environments, enhancing the expression of in vivo-like disease phenotypes.

The technology may facilitate the maturation of patient-derived organoids and the development of personalized disease models, addressing challenges associated with unpredictable growth patterns and substantial heterogeneity seen in traditional in vitro techniques. Regenerative medicine emerges as another promising application, with organoids serving as an unlimited source of regenerative tissue. Organoids-on-a-chip may contribute to optimizing conditions for in vitro expansion of organoids, potentially overcoming efficiency and safety concerns associated with transplantation.


Exciting possibilities include engineering advanced anatomical and physiological features, such as vasculature and nerves, into organoids during in vitro expansion, opening new frontiers in regenerative medicine. Despite these opportunities, challenges exist for organoids-on-a-chip technology. Current models are often predetermined and struggle to capture dynamic structural, environmental, and functional changes during organogenesis. Efforts are required to understand the spatiotemporal dynamics of organ development and devise advanced engineering techniques to reproduce evolving organs in micro engineered organoid cultures.

Biomaterials with well-defined properties are needed to replace hydrogels with batch-to-batch variability. Concerns about polydimethylsiloxane's absorption of small molecules in microdevice fabrication are being addressed through studies exploring alternative materials and surface engineering techniques. For integrated multiorgan models, further investigations are needed to identify optimal culture conditions and media compositions for coculture of various cell types. Challenges related to the three-dimensionality and structural complexity of engineered organoid constructs may be addressed through innovative device designs, tissue-clearing methods, and advanced 3D imaging techniques. Despite all these challenges, the fusion of organoids with organs-on-a-chip technology represents a wave of innovation with continued evolution, promising even greater advancements in the field. The collaborative exchange of ideas, perspectives, expertise, and resources between physical and biological sciences is driving this transformative effort, shaping a future where the full potential of organoids is yet to be realized.

All the findings are visually represented within figure 8 and 9 with descriptions. There are various biomaterials in tissue engineering which are used and available for experimentation which are provided in table 1 with their associated advantages, disadvantages, or limitations.



 $\textbf{Figure 8.} \ A \ Summarization \ of the \ findings \ involved \ concerning \ the \ research \ exploration \ 1$



 $\textbf{Figure 9.} \ A \ Summarization \ of the findings involved concerning the research exploration \ 2$

Table 1. The Different Biomaterials used for Tissue Engineering

Advantages, Disadvantages, or Limitations of Different Biomaterials Used for Tissue Engineering							
No.	Biomaterial	Advantages	Disadvantages/limitations	Types of tissue engineering products			
A	A Polymers 3D, three-dimen			sional; ECM, extracellular matrixes			
1	Natural polymers	BiocompatibilityCell adhesion motifsHigh processabilityElasticityDegradability	Limited mechanical properties	Various tissues such as heart, bone, liver, and cartilage			
2	ECM	Mimicking native tissue		Tissues such as bone, skin, meniscus, and kidney			

3	Synthetic polymers	Can be bioresorbable and processed in a controlled way High mechanical properties	Inflammation No cell adhesion molecules	Tissues such as bone, cartilage, nerve, and brain
4	Hydrogels	 Cells, drugs, and biomolecule delivery Minimally invasive techniques 	 Mechanical properties Adhesive strength Cell adhesion	 3D bioprinting Injectable materials and drug delivery vehicles for regeneration Minimally invasive regenerative therapeutics Cartilage regeneration
5	Smart and functional polymers—composites	 Biological properties Antibacterial activity Physical properties, e.g., self-healing, shape-memory, stimuli-responsiveness 	Controllability of responsiveness may be affected by environment	Injectable regenerative therapeutics for treating bone defects
В	Bioceramics	Bioactive Biocompatible High compression strength 3D printed scaffolds with mechanical characteristics comparable to human cortical bone	 Low tensile strength Brittleness Weak under cyclic or high loads 	Hard tissue engineering such as bone, cartilage, and tooth
С	Ceramic- polymer composites	Cell incorporationEnhanced tissue infiltration	Brtittleness	• Injectable or 3D-printed composites for dental and cartilage tissue engineering
D	Metals	BiocompatibilityDegradable metal alloysImproved mechanical properties	Uncontrolled corrosion	Absorbable implants for bone repair3D porous scaffolds

13. Discussions

In the expansive landscape of tissue engineering, characterized by over 100,000 publications and 9,000 patents, numerous challenges persist, hindering seamless translation to clinical applications. Despite significant advancements, the collaboration between academia, industry, clinical investigators, and clinicians remains underdeveloped, necessitating intensified efforts to bridge scientific challenges with translational potential for meaningful patient impact. Key among these challenges is the need to address cell death within scaffolds post-implantation, where the limitations of nutrient diffusion impact cell survival. Strategies have emerged to sustain cell viability, particularly in the context of complex 3D-bioprinted tissue constructs, through the use of O2generating biomaterials. Accurate cell positioning and the incorporation of angiogenic growth factors are recognized as essential for successful tissue engineering. Ensuring proper blood supply is crucial to prevent construct failure and enhance tissue integration. Additionally, the immunocompetent response to implanted constructs poses a complex challenge, prompting exploration into strategies such as utilizing autologous cells, biocompatible materials, and immunemodulating agents to mitigate immune reactions. Construct durability is a critical consideration, necessitating long-term studies to assess functionality accurately. Innovations in in vivo imaging, cell tracking, and sensor technology provide enhanced monitoring capabilities during the postimplantation period, facilitating timely interventions if issues arise. Overcoming size limitations in engineered tissues, particularly in hard tissues like bone, remains a significant challenge. Strategies involving supportive structures and sacrificial materials are under exploration to address this limitation effectively. Ethical concerns, including the source of cells and the risks associated with unregulated stem cell therapies, demand attention.

Regulatory approvals, financial considerations, and patient acceptance pose additional challenges in the wider clinical application of engineered tissues. Looking towards the future, anticipated trends in tissue engineering include the advancement of in situ tissue engineering, leveraging bioresponsive materials and advanced bioprinting techniques for minimally invasive therapeutic delivery. This approach holds promise for revolutionizing regenerative medicine by enabling precise control over tissue architecture and cell distribution, ultimately leading to improved treatment outcomes. Additionally, the integration of sensors and monitoring devices within engineered tissues will enable real-time assessment of tissue function and response to treatment, enhancing patient monitoring and facilitating personalized medicine. Strengthening collaboration between academia, industry, clinical investigators, and clinicians is essential for overcoming translational challenges in tissue engineering. Interdisciplinary research efforts, coupled with strategic partnerships, will facilitate the development of innovative solutions and accelerate the translation of research findings into clinical practice, ultimately benefiting patients worldwide.

14. Conclusions

The integration of induced pluripotent stem cells (iPSCs), stem cell-derived extracellular vesicles (EVs), and 3D printing facilitates the development of customized treatment modalities. Electroconductive materials open new frontiers, particularly in neural tissue engineering, while the incorporation of sensors and actuators enables real-time monitoring and intervention. The Internet of Things (IoT) advances diagnosis, treatment design, implant installation, and optimization. Microfluidic Organ-on-Chip systems offer opportunities for studying tissues, disease models, and drug testing in tissue engineering.

Next-generation studies will emphasize smart biomaterials, stem cell research, nanotechnology, bio fabrication techniques, synthetic biology integration, and the application of computer modeling, artificial intelligence (AI), and 3D printing for real-time understanding of cell-material interactions. The overarching goal is to enhance biocompatible smart material usage in tissue engineering applications to meet patient needs effectively.

The trajectory of organoid technology is moving towards the development of more sophisticated models that closely mimic in vivo structures and functions. Rather than solely focusing on prominent markers or functional assays, a shift towards architectural benchmarking of native tissues is emphasized. For instance, while hepatocyte organoids preserve hepatocyte functions, their tissue architecture does not replicate the native tissue where hepatocytes are arranged in cords. Complex functions require organoids with multicellular and multi-tissue structures, highlighting the importance of studying cell-cell interactions, leading to the emergence of more complex models like assembloids and organs-on-chips. On the contrary, the engineer's approach advocates for simpler reductionist models, defined by minimal functional modules driving specific cellular or tissue functions. This reductionist strategy aims to decipher the mechano-biological causation in development or repair, enabling high-throughput screening. It assumes that complex biological functions result from the coordinated operation of a limited number of functional modules, each described by a small set of molecules and chemical reactions. Geometric constraints, such as micropatterning and 2.5D culture, are employed to induce tissue-like morphogenesis, leading to highly reproducible structures, facilitating mechanistic understanding of tissue morphogenetic events. The reduction of the third dimension in a 2.5D culture is a key technique, minimizing variabilities associated with typical organoid culture.

This approach, restricting cells on curved or patterned surfaces or overlaying the extracellular matrix on a flat cell monolayer, enhances imaging transparency and reduces depth-driven variabilities. Technological advancements, including CRISPR-edited cells for disease modeling, are anticipated to contribute to the development of more engineered organoid models.

A key component of personalized medicine is mechanobiology, which studies how mechanical stresses affect biological behavior. Understanding and treating illness depend on how cells interact with their surroundings, particularly the extracellular matrix (ECM). Research focuses on developing artificial substrates to show how the matrix features affect all the important biological functions, such as hydrogel-based systems. Understanding of mechanotransduction is improved by active biomaterials that replicate dynamic microenvironments. Differential mechanoresponses are triggered by temporal variations in force resistance and stress exposure, leading to dynamic cell shape, focal adhesion, and nuclear translocation alterations. Force, duration, and timing all influence responses; temporal elements are complicated by the idea of mechanical memory.

Active biomaterials that control biological reactions by means of resistance or external pressures represent various types of the significant advancements. Exact control is made possible by photosensitive and magnetically triggered techniques, which open new avenues for studying the influence of force on cellular choices. Leading the way in developing novel treatment approaches based on cellular mechanical reactions is mechanobiology.

The impact of these advancements is foreseen in various applications, including replacing animal testing, gaining regulatory acceptance, and widespread adoption of organoids in cell therapy, regenerative medicine, in vitro diagnostics, and drug discovery. This paradigm shift indicates a growing confidence in the viability of organoids as alternatives to traditional research methods and a promising future for their diverse applications. Developments in active biomaterials and synthetic substrates make it possible to recreate and investigate dynamic mechanical microenvironments, which are essential for in vivo cellular experiences. Mechanobiology's temporal component, which spans from early reversible reactions to persistent downstream effects, adds complexity and begs for more research. Designing treatments with long-lasting effects requires an understanding of the molecular principles behind cellular resistance to mechanical stimulation.

The future lies on utilizing in silico organoid models and microfabrication developments to integrate mechanobiology into personalized medicine. As the complexity of mechanotransduction is revealed, expectations for new personalized treatment approaches that take into account the mechanical properties of each patient's cellular milieu are growing.

Acknowledgments

The main prospect and the scope for this research was conducted and idea perspective investigations with the manuscript writing was done by the authors themselves. All the datasets, data tools, data models, data sources which have been retrieved and used for the conduction of this research are mentioned and referenced where appropriate.

References

[1] Smit, Theodoor H. (2020). "Adolescent idiopathic scoliosis: The mechanobiology of differential growth". JOR Spine. **3** (4): e1115. doi:10.1002/jsp2.1115. ISSN 2572-1143. PMC 7770204. PMID 33392452. S2CID 225497216.

- [2] Tracy, Lauren E.; Minasian, Raquel A.; Caterson, E.J. (March 2016). "Extracellular Matrix and Dermal Fibroblast Function in the Healing Wound". Advances in Wound Care. 5 (3): 119–136. doi:10.1089/wound.2014.0561. ISSN 2162-1918. PMC 4779293. PMID 26989578.
- [3] Korhonen, R.K; Laasanen, M.S; Töyräs, J; Rieppo, J; Hirvonen, J; Helminen, H.J; Jurvelin, J.S (July 2002). "Comparison of the equilibrium response of articular cartilage in unconfined compression, confined compression and indentation". Journal of Biomechanics. **35** (7): 903–909. doi:10.1016/s0021-9290(02)00052-0. ISSN 0021-9290. PMID 12052392.
- [4] Xia, Yuntao; Pfeifer, Charlotte R.; Cho, Sangkyun; Discher, Dennis E.; Irianto, Jerome (2018-12-21). del Río Hernández, Armando (ed.). "Nuclear mechanosensing". Emerging Topics in Life Sciences. 2 (5): 713–725. doi:10.1042/ETLS20180051. ISSN 2397-8554. PMC 6830732. PMID 31693005.
- [5] Mammoto, Akiko; Mammoto, Tadanori; Ingber, Donald E. (2012-07-01). "Mechanosensitive mechanisms in transcriptional regulation". Journal of Cell Science. **125** (13): 3061–3073. doi:10.1242/jcs.093005. ISSN 0021-9533. PMC 3434847. PMID 22797927.
- [6] Wu Y, Zhu S, Lv Z, Kan S, Wu Q, Song W, et al. (December 2019). "Effects of therapeutic ultrasound for knee osteoarthritis: a systematic review and meta-analysis". Clinical Rehabilitation. **33** (12): 1863–1875. doi:10.1177/0269215519866494. PMID 31382781. S2CID 199452082.
- [7] Uddin SM, Komatsu DE, Motyka T, Petterson S (June 2021). "Low-Intensity Continuous Ultrasound Therapies—A Systematic Review of Current State-of-the-Art and Future Perspectives". Journal of Clinical Medicine. **10** (12): 2698. doi:10.3390/jcm10122698. PMC 8235587. PMID 34207333.
- [8] Leighton R, Phillips M, Bhandari M, Zura R (June 2021). "Low intensity pulsed ultrasound (LIPUS) use for the management of instrumented, infected, and fragility non-unions: a systematic review and meta-analysis of healing proportions". BMC Musculoskeletal Disorders. **22** (1): 532. doi:10.1186/s12891-021-04322-5. PMC 8196464. PMID 34116673.
- [9] Ebadi S, Henschke N, Forogh B, Nakhostin Ansari N, van Tulder MW, Babaei-Ghazani A, Fallah E, et al. (Cochrane Back and Neck Group) (July 2020). "Therapeutic ultrasound for chronic low back pain". The Cochrane Database of Systematic Reviews. **2020** (7): CD009169. doi:10.1002/14651858.CD009169.pub3. PMC 7390505. PMID 32623724.
- [10] Papadopoulos ES, Mani R (December 2020). "The Role of Ultrasound Therapy in the Management of Musculoskeletal Soft Tissue Pain". The International Journal of Lower Extremity Wounds. **19** (4): 350–358. doi:10.1177/1534734620948343. PMID 32856521. S2CID 221358210.
- [11] Hameroff, Stewart (2013). "Transcranial ultrasound (TUS) effects on mental states: A pilot study" (PDF). Brain Stimulation. Elsevier. **6** (3): 409–15. doi:10.1016/j.brs.2012.05.002. PMID 22664271. S2CID 206354818. Archived from the original (PDF) on 22 March 2013. Retrieved 25 October 2013.
- [12] Daffertshofer, M. (2005). <u>"Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial"</u>. Stroke. **36** (7): 1441–6. <u>doi:10.1161/01.STR.0000170707.86793.1a</u>. PMID 15947262.
- [13] Tyler, Dr. William J. "Remote Control of Brain Activity Using Ultrasound". Armed with Science. U.S. Defense Department. Retrieved 21 February 2016.
- [14] Zhang, Boyang; Korolj, Anastasia; Lai, Benjamin Fook Lun; Radisic, Milica (2018-08-01). "Advances in organ-on-a-chip engineering". Nature Reviews Materials. **3** (8): 257–278. Bibcode:2018NatRM...3..257Z. doi:10.1038/s41578-018-0034-7. ISSN 2058-8437. S2CID 69815527.
- [15] Ingber, Donald E. (2022-03-25). "Human organs-on-chips for disease modelling, drug development and personalized medicine". Nature Reviews Genetics. Springer Science and Business Media LLC. 23 (8): 467–491. doi:10.1038/s41576-022-00466-9. ISSN 1471-0056. PMC 8951665. PMID 35338360.

- [16] Wiest, J (January 2022). "Systems engineering of microphysiometry". Organs-on-a-Chip. **4**: 100016. doi:10.1016/j.ooc.2022.100016. S2CID 245970804.
- [17] Tang H, Abouleila Y, Si L, Ortega-Prieto AM, Mummery CL, Ingber DE, Mashaghi A (November 2020). "Human Organs-on-Chips for Virology". Trends Microbiol. **28** (11): 934–946. doi:10.1016/j.tim.2020.06.005. PMC 7357975. PMID 32674988.
- [18] Liu H, Bolonduro OA, Hu N, Ju J, Rao AA, Duffy BM, et al. (April 2020). "Heart-on-a-Chip Model with Integrated Extra- and Intracellular Bioelectronics for Monitoring Cardiac Electrophysiology under Acute Hypoxia". Nano Letters. **20** (4): 2585–2593. <u>Bibcode:2020NanoL..20.2585L.doi:10.1021/acs.nanolett.0c00076</u>. <u>PMID</u> 32092276. <u>S2CID</u> 211476393.
- [19] Mu X, Zheng W, Xiao L, Zhang W, Jiang X (April 2013). "Engineering a 3D vascular network in hydrogel for mimicking a nephron". Lab on a Chip. **13** (8): 1612–8. doi:10.1039/c3lc41342j. PMID 23455642.
- [20] Kang YB, Sodunke TR, Lamontagne J, Cirillo J, Rajiv C, Bouchard MJ, Noh M (December 2015). "Liver sinusoid on a chip: Long-term layered co-culture of primary rat hepatocytes and endothelial cells in microfluidic platforms". Biotechnology and Bioengineering. 112 (12): 2571–82. doi:10.1002/bit.25659. PMID 25994312. S2CID 41351732.
- [21] Kirby BJ (2010). Micro- and Nanoscale Fluid Mechanics: Transport in Microfluidic Devices. Cambridge University Press. Archived from the original on 2019-04-28. Retrieved 2010-02-13.
- [22] Chokkalingam V, Weidenhof B, Krämer M, Maier WF, Herminghaus S, Seemann R (July 2010). "Optimized droplet-based microfluidics scheme for sol-gel reactions". Lab on a Chip. **10** (13): 1700–1705. doi:10.1039/b926976b. PMID 20405061.
- [23] Thomas DJ, McCall C, Tehrani Z, Claypole TC (June 2017). "Three-Dimensional—Printed Laboratory-on-a-Chip With Microelectronics and Silicon Integration". Point of Care. **16** (2): 97–101. doi:10.1097/POC.00000000000132. S2CID 58306257.
- [24] Berthier J, Brakke KA, Berthier E (2016-08-01). Open Microfluidics. doi:10.1002/9781118720936. ISBN 9781118720936.
- [25] Lade, R. K.; Jochem, K. S.; Macosko, C. W.; Francis, L. F. (2018). "Capillary Coatings: Flow and Drying Dynamics in Open Microchannels". Langmuir. 34 (26): 7624–7639. doi:10.1021/acs.langmuir.8b00811. PMID 29787270.
- [26] Mahla RS (2016). "Stem cells application in regenerative medicine and disease threpeutics". International Journal of Cell Biology. **2016** (7): 1–24. doi:10.1155/2016/6940283. PMC 4969512. PMID 27516776.
- [27] "Research". Institute for Stem Cell Biologyand Regenerative Medicine. Retrieved 2020-02-25.
- [28] Mahla RS (2016). "Stem cells application in regenerative medicine and disease threpeutics". International Journal of Cell Biology. **2016** (7): 1–24. doi:10.1155/2016/6940283. PMC 4969512. PMID 27516776.
- [29] Nguyen, D. X.; Bos, P. D.; Massague, J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 2009, 9, 274–284.
- [30] Dang, A. P.; De Leo, S.; Bogdanowicz, D. R.; Yuan, D. J.; Fernandes, S. M.; Brown, J. R.; Lu, H. H.; Kam, L. C. Enhanced activation and expansion of T cells using mechanically soft elastomer fibers. Adv. Biosyst. 2018, 2, 1700167.
- [31] Akhmanova M, Osidak E, Domogatsky S, Rodin S, Domogatskaya A (2015) Physical, spatial, and molecular aspects of extracellular ma- trix of in vivo niches and artificial scaffolds relevant to stem cells research. Stem Cells Int 35

- [32] D. Wirtz, K. Konstantopoulos, P.C. Searson, "The physics of cancer: the role of physical interactions and mechanical forces in metastasis, Nat. Publ. Gr. 11 (7) (2011) 512–522, https://doi.org/10.1038/nrc3080.
- [33] K.R. Levental, H. Yu, L. Kass, J.N. Lakins, M. Egeblad, J.T. Erler, S.F.T. Fong, K. Csiszar, A. Giaccia, W. Weninger, M. Yamauchi, D.L. Gasser, V.M. Weaver, Matrix crosslinking forces tumor progression by enhancing integrin signaling, Cell 139 (5) (2009) 891–906, https://doi.org/10.1016/j.cell.2009.10.027.